Looking through the recent top 20 announcement I noticed that Mr Edmund Hugh Conyber Kelly was a new top 20 shareholder with a 256400 share stake. Not sure if there is any relation to Graham Kelly (info below).
Dr Graham E Kelly: Executive Director since T994, Dr Kelly is founder and was the first Managing Director of Novogen limited. Dr Kelly was Chairman of the Novogen Gloup until the 31 December 2000 a position he had held since March 1997, he is also Chairman of subsidiary company Marshall Edwards, Inc. He has spent nearly 30 years in medical research involving drug development, immunology, surgery and cancer. Dr Kelly was Seniof Research Fellow in Experimental Surgery in the Faculty of Medicine at the University of Sydney. He developed the B-l, 3-Giucan and Isoflavonoid compounds now o m e d by the Novogen Group.
NRT Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
